Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy
L Leclair-Visonneau, T Rouaud, B Debilly… - Clinical neurology and …, 2016 - Elsevier
Objectives Results from preclinical studies suggest that inhibition of glycogen synthase
kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was
therefore to determine the effects of sodium valproate (VPA), a GSK-3 inhibitor, on disease
progression in progressive supranuclear palsy (PSP). Patients and methods We performed
a double-blind, randomized, placebo-controlled trial, in 28 PSP patients who received VPA
(1500 mg/day) or matching placebo for 24 months. The primary endpoint was the change …
kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was
therefore to determine the effects of sodium valproate (VPA), a GSK-3 inhibitor, on disease
progression in progressive supranuclear palsy (PSP). Patients and methods We performed
a double-blind, randomized, placebo-controlled trial, in 28 PSP patients who received VPA
(1500 mg/day) or matching placebo for 24 months. The primary endpoint was the change …